Zacks Investment Research cut shares of Selecta Biosciences Inc. (NASDAQ:SELB) from a buy rating to a hold rating in a report issued on Wednesday morning.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

Other equities research analysts have also issued research reports about the company. Needham & Company LLC started coverage on Selecta Biosciences in a research note on Monday, July 18th. They set a buy rating and a $28.00 price target for the company. Canaccord Genuity started coverage on Selecta Biosciences in a research note on Monday, July 18th. They set a buy rating and a $20.00 price target for the company. Finally, Stifel Nicolaus started coverage on Selecta Biosciences in a research note on Monday, July 18th. They set a buy rating and a $23.00 price target for the company.

Shares of Selecta Biosciences (NASDAQ:SELB) traded down 0.88% on Wednesday, reaching $15.81. The company’s stock had a trading volume of 1,063 shares. The company’s 50 day moving average price is $13.87 and its 200 day moving average price is $13.32. Selecta Biosciences has a 12-month low of $10.26 and a 12-month high of $18.88.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Monashee Investment Management LLC acquired a new position in shares of Selecta Biosciences during the second quarter worth about $350,000. Laurion Capital Management LP acquired a new position in shares of Selecta Biosciences during the second quarter worth about $350,000. Marshall Wace LLP acquired a new position in shares of Selecta Biosciences during the second quarter worth about $506,000. Vanguard Group Inc. acquired a new position in shares of Selecta Biosciences during the second quarter worth about $1,679,000. Finally, FMR LLC acquired a new position in shares of Selecta Biosciences during the second quarter worth about $3,997,000. Institutional investors own 41.02% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

5 Day Chart for NASDAQ:SELB

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.